Dry extract from Yohimbe – Supports the normal fat burning process and increases sexual desire and libido*
How and Why It Works?
VemoHerb® Yohimbe is a dietary supplement based on dry plant extract from Pausinystalia yohimbe, with an active ingredient – the indolalkylamine alkaloid yohimbine hydrochloride. It is considered part of the beta-carbolines of the indol alkaloids group and is isolated from the Rubaceae plants family. It is standardized according to indices which are present in the European pharmacopoeia as yohimbine hydrochloride and is studied mainly in two directions – as yohimbine salts of mineral acids, hydrochloric and nitric; and as an active ingredient in extracts from the bark of Yohimbe tree (Pausinystalia yohimbe). As a non-essential active substance, yohimbine is not produced in the body and is often absent in the bloodstream, unless supplemented.
Intake of the dietary supplement VemoHerb® Yohimbe increases the yohimbine levels in the blood, which support the blood circulation in the whole body and especially the part of the spinal cord which is responsible for the erectile functions.* [1 – 3] That leads to enhanced sexual desire and satisfaction and is beneficial in cases of low libido.* 
The physiological properties of the extracts containing yohimbine are quite well studied. The main research directions are in the positive effects on weight loss (fat burning), and increased libido.* [1 – 7] Some studies suggest that yohimbine has aphrodisiac properties, especially in cases of mild sexual deficiencies connected to age.* [1 – 4]
VemoHerb® Yohimbe can significantly decrease fat levels.* [5 – 7] It increases the energy levels of the body during daily trainings for bodybuilders and athletes.* [8 – 9]
VemoHerb® Yohimbe is also applied in terms of the impact of its antioxidant potential on the fat burning process by increasing the free fatty acid levels.* [4, 5, 6, 9] Another study suggests that the effect of yohimbine is defined as a blocker of α-receptors, which slows down the oxidation (metabolism) of fats.*  Thus, the supplement could aid the normal fat burning process.* It assists regulation of the body’s energy levels during training for bodybuilders and athletes.* [8 – 9]
Fatty acids are a basic source of energy, and when they are incorporated in fats – they are stored and not used – you gain weight. However, when they are released from the fats, they provide for energy that is used for muscle building for example. So, while supplementing yourself with VemoHerb® Yohimbe you end up with less fat and more free energy for training.*
VemoHerb® Yohimbe is recommended for:
good sexual health for men*
supporting the central nervous system* [10 – 11]
body fat weight loss*
The pack contains
Active substances in one capsule
2 mg dry extract of Pausinystalia yohimbe, with content of 98% yohimbine hydrochloride
Recommended daily dose
Take 1 capsule 2 times a day.
For sportsmen: Take 1-2 capsule 3 times a day (one intake just before training).
Directions for use
Take between the meals or as directed on the label.
The product is a food supplement not a medical drug. The product is not a substitute for a varied diet. Do not exceed the recommended daily dose. It is not recommended for pregnant, nursing women and children!
1. Smith, E. and Davidson, J. (1990) – Yohimbine attenuates aging-induced sexual deficiencies in male rats. Physiology & Behavior, 47(4), pp.631-634.
Since yohimbine strongly stimulates sexual motivation/arousal in rats, it was of interest to determine whether the arousal deficit in aging male rats could be reversed by yohimbine. Three groups from each of two ages (approximately 3 and 15 months) received vehicle, 1 or 4 mg/kg yohimbine. In the mounting test (for arousal/motivation), 1 mg/kg yohimbine significantly increased mount frequency in middle-aged rats, though not to the level of the young animals. In the mating test, the percentage of aging rats intromitting and displaying ejaculatory behavior was less than in the young group, but after 1 mg/kg yohimbine, these behaviors were significantly increased. Vehicle-treated middle-aged rats which had mated showed significantly elevated intercopulatory intervals and ejaculatory behavior latencies. These measures were reduced by 1 mg/kg yohimbine. While behavioral facilitation following yohimbine in aging rats did not reach that of young yohimbine-treated rats, they reached levels at or close to those of nontreated young animals. We conclude that yohimbine treatment can improve age-related deficits seen to occur in aging male rat sexual behavior.
2. Saad, M., Eid, N., Abd El-Latif, H. and Sayed, H. (2013) – Potential effects of yohimbine and sildenafil on erectile dysfunction in rats. European Journal of Pharmacology, 700(1-3), pp.127-133.
In this study the effects of yohimbine and sildenafil on cold stress-induced erectile dysfunction in rats were investigated. Yohimbinehydrochloride (0.2 mg/kg, i.p.) and sildenafil citrate (20 mg/kg, i.p) were administered to rats 1h before the stress session daily for 14 consecutive days and their effect was assessed. Results of this section revealed that, immersion of rats in cold water significantly decreased sexual arousal and motivation as indicated by increased latencies and intervals. Furthermore decreased copulatory performance and potency as indicated by decreased ejaculation frequency was observed. Decreased copulatory activity was confirmed by decreased testosterone, luteinizing hormone (LH) and follicle-stimulating-hormone (FSH) levels as well as decreased cholesterol content in rat testes. Treatment with yohimbine or sildenafil significantly increased the sexual arousal and potency and corrected the effects induced by stress on the mating behavior of male rats. On the contrary they did not significantly alter testosterone, FSH and LH levels which is reflected by failure of both drugs to alter cholesterol content in rat testes. Regarding the effect of yohimbine and sildenafil on isolated rat corpus cavernosum, their cumulative dose response curves (3×10(-7), 3×10(-6) and 3×10(-5) M) were determined in corpus cavernosum strips isolated from normal rats and pre-contracted with phenylephrine (3×10(-6) M) were also assessed. Results of this part showed that both yohimbine and sildenafil have a relaxant effect on rat corpus cavernosum strips in a dose dependant manner, which is confirmed by the increase in nitric oxide content in rats’ penis shown bysildenafil.
3. Vogt, H., Brandl, P., Kockott, G., Schmitz, J., Wiegand, M., Schadrack, J. and Gierend, M. (1997) – Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. International Journal of Impotence Research, 9(3), pp.155-161.
This double-blind, placebo-controlled clinical trial of yohimbine hydrochloride included 86 patients with erectile dysfunction and without clearly detectable organic or psychologic causes. The patient group fulfilled all entry criteria; 85 of these could be considered for the Safety-respectively 83 for the Intention-to-treat (ITT)-analysis. Yohimbine was administered orally in a dosage of 30 mg a day (two 5 mg tablets three times daily) for eight weeks. Patients were seen for follow-up after four weeks’ treatment, and for a final visit after eight weeks. Efficacy evaluation was based on both subjective and objective criteria. Subjective criteria included improvement in sexual desire, sexual satisfaction, frequency of sexual contacts, and quality of erection (penile rigidity) during sexual contact/intercourse. Objective criteria of outcome were based on improvement in penile rigidity determined by use of polysomnography in the sleep laboratory. Overall Yohimbine was found significantly more effective than placebo in terms of response rate: 71 vs 45%. Yohimbine was well-tolerated: Only 7% of patients rated tolerability fair or poor, and most adverse experiences were mild. There was no serious adverse event.
4. Peter Lim Huat Chye – Traditional Asian folklore medicines in sexual health
The results of four independent yet convergent meta-analyses to examine the efficacy of yohimbine in the treatment of erectile disorder are reported. These meta-analyses integrated data from (i) controlled clinical trials of yohimbine (when used alone), (ii) uncontrolled trials examining yohimbine (alone), (iii) controlled trials of yohimbine when used in combination with other drugs, and (iv) uncontrolled trials of yohimbine plus other drugs. Results document a consistent tendency for yohimbine, and for other medications containing yohimbine, to enhance erectile functioning relative to placebo. We also identify methodological and reporting difficulties that characterize much of the literature.
5. Galitzky, J., Taouis, Berlan, Rivière, Garrigues, and Lafontan (1988) – α2-Antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. European Journal of Clinical Investigation, 18(6), pp.587-594.
Investigations were carried out to analyse the interactions of alpha 2-antagonists (yohimbine, idazoxan, SK & F-86,466) with human fat cell alpha 2-adrenoceptors. All the alpha 2-antagonists enhanced the lipolytic potencies of epinephrine with an order of potency: yohimbine greater than idazoxan greater than SK & F-86,466; the same order was also found in 3H-yohimbine competition studies on human fat cell membranes. The most potent agent, yohimbine, was administered orally in humans to define the conditions of appearance and the time-course of a putative lipid-mobilizing action. Oral yohimbine administration (0.2 mg kg-1) elevated plasma glycerol and non-esterified fatty acids in fasting healthy subjects without significant action on heart rate or blood pressure during the time-course of the experiment. The lipid-mobilizing action of yohimbine was reinforced during physical exercise, completely suppressed after a meal and partially blocked by administration of propranolol (0.5 mg kg-1; 60 min before yohimbine). Plasma norepinephrine concentrations were increased (40-50%) after oral yohimbine administration. The rise in plasma catecholamine concentration elicited by yohimbine was not modified by propranolol treatment. The lipid-mobilizing effect of yohimbine could be attributable to: (i) the increase in synaptic norepinephrine with a resultant increment in lipolysis by beta-adrenergic agonism; (ii) a decrease in alpha 2-adrenoceptor stimulation of human fat cell alpha 2-adrenoceptors; (iii) a blockade of presynaptic alpha 2-adrenoceptors. The use of highly selective alpha 2-antagonists will allow investigations into alpha 2-adrenoceptors, which may represent a novel locus for pharmacological intervention in lipid-mobilization strategies.
6. Lafontan, M., Berlan, M., Galitzky, J. and Montastruc, J. (1992) – Alpha-2 adrenoceptors in lipolysis: α2 antagonists and lipid-mobilizing strategies. The American Journal of Clinical Nutrition, 55(1), pp.219S-227S.
The lipid-mobilizing and thermogenic effects of several alpha 2 antagonists were explored. Studies were undertaken in humans and in the dog, which possess fat-cell alpha 2-adrenergic receptors (alpha 2-AR) and beta-adrenergic receptors (beta-AR) that are very similar. Yohimbine (alpha 2-AR antagonist) was used in humans whereas other recent alpha 2 antagonists were used in dogs. Oral yohimbine (0.2 mg/kg) promoted a lasting increment of plasma nonesterified fatty acids (NEFAs) and noradrenaline concentrations without significant action on cardiovascular parameters or insulin secretion. In dogs, a direct correlation between the variations of plasma NEFA and noradrenaline concentrations induced by alpha 2 antagonists (1.2 mmol/kg iv) was observed; a result supporting the relationship between lipolysis and the pharmacologic activation of the sympathetic nervous system. Cardiovascular effects were almost absent whereas a long-lasting thermogenic effect was observed. The lipid-mobilizing effect of alpha 2 antagonists is mainly attributable to the increase in synaptic noradrenaline. The potential interest of alpha 2 antagonists in diet therapy is discussed.
7. Greenway FL, Bray GA. – Regional fat loss from the thigh in obese women after adrenergic modulation. Clin Ther 1987; 9: 663-669.
Beta-adrenergic stimulation and alpha 2-adrenergic inhibition increase lipolysis from fat cells. Twenty-eight obese women were placed on a calorie-restricted diet and one of five treatments was applied to one thigh three to five times per week for four weeks: (1) isoproterenol injections; (2) cream containing colforsin (forskolin), aminophylline, and yohimbine; (3) yohimbine cream; (4) colforsin cream; or (5) aminophylline cream. The opposite thigh was treated with a placebo (injection or cream). The treated thighs lost significantly more girth after treatment, both by injection and by cream. No adverse reactions were attributable to either the cream or the injections. It is concluded that local fat reduction from the thigh can be safely accomplished.
8. McCarty, M. (2002) – Pre-exercise administration of yohimbine may enhance the efficacy of exercise training as a fat loss strategy by boosting lipolysis. Medical Hypotheses, 58(6), pp.491-495.
The natural alpha-2 antagonist yohimbine promotes sympathetic activity by central as well as peripheral mechanisms, and yet in moderate doses dose not usually raise heart rate, increase blood pressure, or induce anxiety (in contrast to sympathomimetic drugs such as ephedrine). Administered prior to exercise, it boosts lipolysis and serum FFA levels both during and following exercise; blockade of adipocyte alpha-2 adrenoreceptors makes at least a modest contribution to this pro-lipolytic activity. These considerations suggest that pre-exercise administration of yohimbine will lower the respiratory quotient during and following exercise, thus promoting fat loss. Since yohimbine can potentiate postprandial insulin secretion, its bariatric benefits should be greatest if administered on a schedule that minimizes postprandial yohimbine activity. A possible synergism of yohimbine and caffeine should be explored. Pre-exercise yohimbine administration has the potential to down-regulate the lipoprotein lipase activity of visceral adipocytes, increase lipolysis in refractory gynoid fat depots, and improve the impaired lipolytic response to exercise in the elderly.
9. Ostojic, S. (2006) – Yohimbine: The Effects on Body Composition and Exercise Performance in Soccer Players. Research in Sports Medicine, 14(4), pp.289-299.
The main aim of this study was to determine the effects of yohimbine supplementation on body composition and exercise performance in professional soccer players. The athletes (20 top-level male soccer players) were allocated to two randomly assigned trials. Subjects in the yohimbine group orally ingested tablets that contains yohimbine at a dose of 20 milligrams per day in two equal doses for 21 days. Subjects in the placebo group ingested an equal number of identical-looking pills that contained cellulose. There were no statistically significant changes in body mass and muscle mass within or between trials (p > 0.05) after the supplementation protocol. Percentage of body fat significantly decreased in the yohimbine group after the supplementation protocol (9.3 +/- 1.1 vs. 7.1 +/- 2.2%; p < 0.05). Furthermore, fat mass was significantly lower in the yohimbine versus placebo trial at postsupplementation assessment (7.1 +/- 2.2 vs. 9.2 +/- 1.9%; p < 0.05). There were no changes in exercise performance indicators (bench and leg press, vertical jump, dribble and power test results, shuttle run) within or between. trials (p > 0.05). No subject reported any side effects from yohimbine. The results of the current study indicate that supplementation with yohimbine combined with resistance training does not significantly alter the body mass, muscle mass, or performance indicators in professional soccer players. Nonetheless, yohimbine supplementation appears to be suitable as a fat loss strategy in elite athletes.
10. Peskind, E. (1995) – Effects of Alzheimer's Disease and Normal Aging on Cerebrospinal Fluid Norepinephrine Responses to Yohimbine and Clonidine. Archives of General Psychiatry, 52(9), p.774.
The resting cerebrospinal fluid (CSF) norepinephrine concentration is unchanged or even increased in patients with Alzheimer’s disease (AD). These in vivo findings appear to be inconsistent with the post-mortem locus ceruleus neuronal loss that is reported in patients with AD. The effects of AD and advanced age on central nervous system noradrenergic status were estimated by comparing CSF norepinephrine concentrations following the administration of yohimbine hydrochloride, clonidine hydrochloride, and placebo in outpatients with AD and older and young normal subjects. Levels of yohimbine, its metabolite 11-hydroxy-yohimbine, and clonidine were measured in CSF and plasma samples. Behavioral responses were quantified by rating the Tension, Excitement, and Anxiety items on the Brief Psychiatric Rating Scale. Yohimbine-induced increases of CSF norepinephrine concentrations were greater in both patients with AD and normal older subjects than in normal young subjects. Clonidine-induced decreases of CSF norepinephrine concentrations did not differ among groups. Behavioral arousal following the administration of yohimbine was greater in patients with AD than in the other groups. Central nervous system noradrenergic responsiveness is enhanced in normal older subjects, and this age effect is retained in patients with AD. Behavioral sensitivity to increased central nervous system noradrenergic activity is enhanced in patients with AD.
11. Ribes, G., Hillaire-Buys, D., Gross, R., Blayac, J. and Loubatières-Mariani, M. (1989) – Involvement of a central nervous pathway in yohimbine-induced insulin secretion. European Journal of Pharmacology, 162(2), pp.207-214.
Yohimbine hydrochloride, an alpha 2-adrenoceptor antagonist, was administered (3.3 mg/kg i.v.) to anesthetized normal dogs provided with a T-shaped catheter inserted in the pancreaticoduodenal vein. The effects on blood glucose levels and pancreatic hormones were investigated. We show that yohimbine induced an immediate and pronounced stimulatory effect on insulin secretionaccompanied by a clear decrease in blood glucose levels. Yohimbine also stimulated the pancreatic secretion of somatostatin and glucagon. However, the secretion kinetics were not the same for the three hormones: the stimulation was rapid and immediate forinsulin and somatostatin, whereas it was progressive for glucagon. All these stimulatory effects were suppressed by propranolol, thus implicating beta-adrenergic mechanisms. Bilateral cervical vagotomy markedly reduced the immediate effect of yohimbine on insulinsecretion, suggesting that a central neural pathway was implicated. In contrast, the progressive elevation in glucagon secretion was not decreased by vagotomy. Our results suggest that yohimbine stimulates, at least in part, insulin secretion by blocking central alpha 2-adrenoceptors.
|*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.